Stockwinners Market Radar for July 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 1.02M shares of Unity today

19:44 EDT Kingswood Acquisition to transfer listing to OTC Markets - Kingswood Acquisition "announced that it had been informed that the New York Stock Exchange had, effective as of approximately 4:00 p.m. Eastern Time on July 13, 2022, suspending trading with respect to KWAC's Class A common stock, redeemable warrants to purchase shares of Class A common stock, and units, each consisting of one share of Class A common stock and three-fourths of one redeemable warrant, due to KWAC's non-compliance with Section 802.01B of the NYSE Listed Company Manual, which requires listed acquisition companies to maintain certain average aggregate global market capitalization standards. The NYSE will apply to the Securities and Exchange Commission to delist the KWAC Securities upon completion of all applicable procedures. KWAC does not intend to appeal the NYSE staff's determination and, accordingly, KWAC expects that the KWAC Securities will be delisted. KWAC intends to transfer the listings of the KWAC Securities to the OTC Markets Group Inc., where KWAC has applied to list the KWAC Securities. KWAC anticipates that the listings of the KWAC Securities will be transferred to and resume trading on the OTC Exchange on or about July 14, 2022."

18:29 EDT United pilots union delays voting on tentative agreement for new talks - United Airlines MEC, the union representing United Airlines pilots, said that a tentative agreement ballot closing has been delayed for new negotiations and pilot surveys. MEC Chair Mike Hamilton said in a video posted on Twitter that the two sides will reopen negotiations on a new contract. Reference Link

18:21 EDT Panasonic to invest roughly $4B in lithium-ion battery plant in Kansas - Panasonic Energy Co., Ltd., a Panasonic Group company, and Kansas Gov. Laura Kelly jointly announced that the state of Kansas has approved an Attracting Powerful Economic Expansion state incentive application submitted by Panasonic Energy Co., Ltd. The agreement would make the state the location for a proposed US-based lithium-ion battery manufacturing facility, pending approval by Panasonic Holdings Corporation Board of Directors. Panasonic Energy plans to develop the project at a property in Kansas, which is expected to drive significant economic activity and opportunities for the local economy and could create up to 4,000 new jobs and result in an investment of approximately $4B. The company has identified a site in De Soto, Kansas for this potential project.

17:39 EDT Tesla AI director Karpathy to leave company - Tesla's director of AI Andrej Karpathy said he is leaving the car maker. "It's been a great pleasure to help Tesla towards its goals over the last 5 years and a difficult decision to part ways," Karpathy said via Twitter. "In that time, Autopilot graduated from lane keeping to city streets and I look forward to seeing the exceptionally strong Autopilot team continue that momentum. I have no concrete plans for what's next but look to spend more time revisiting my long-term passions around technical work in AI, open source and education." Reference Link

17:33 EDT Northern Oil and Gas Chief Strategy Officer Mike Kelly to step down, resign - On July 13, Mike Kelly, Chief Strategy Officer of Northern Oil and Gas, agreed that, effective July 15, he will step down from his position as Chief Strategy Officer and resign as an employee of the company.

17:26 EDT Raytheon Technologies awarded $353.93M Army contract - Raytheon was awarded a $353.93M cost-plus-fixed-fee contract to procure additional lower tier air and missile defense sensor radar prototypes. Bids were solicited via the internet with two received. Work has an estimated completion date of May 1, 2025. FY21 research, development, test and evaluation, Army funds in the amount of $104.81M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:20 EDT Green Brick to replace Coca-Cola Consolidated in S&P 600 at open on 7/20

17:14 EDT ArrowMark Financial Corp. announces June NAV per share $20.93 - ArrowMark Financial Corp. announced that the company's June 30 estimated and unaudited net asset value was $20.94 per share. This NAV reflects the regular second quarter cash dividend of 39c per share, paid on June 29.

17:01 EDT Frequency Electronics names Tom McClelland as interim CEO, Sloane retires - Frequency Electronics is pleased to announce Tom McClelland as Interim CEO, replacing Stanton Sloane who has retired effective July 8 from the company and its Board of Directors. Tom is Frequency's Chief scientist and has been with FEI for almost 40 years. He has led the company's research and scientific efforts for 10 years. He is one of the foremost experts in precision timing and space related applications. He has the highest level of security clearance with the US government and holds a PhD in physics from Columbia University. FEI Chairman General Lance Lord remarks, "We are thrilled to have Tom as our Interim CEO. His expertise in space and timing is one of FEI's and our nation's most vital disciplines for defense and security. Over my career, I have witnessed firsthand the absolute critical nature of high reliable position, navigation and timing information. Military, commercial and civil space and terrestrial networks are rapidly expanding and precision timing is more relevant now to mission success than ever. FEI is at the leading edge of technology innovation and produces the most sophisticated space and terrestrial products. We are going all out to accentuate our position. We have an extremely talented team to execute this mission. The coming period will affirm our success and extreme focus on protecting the US and our allies in this endeavor. Additionally, the Board has tasked independent director and former Chairman Russell Sarachek to lead a team to formulate a comprehensive strategic plan for FEI. This is an exciting period for FEI and the space industry and we will be laser focused on success. We thank Stan for his service to the Company and wish him the best going forward."

16:54 EDT Hannon Armstrong responds to short report, says accounting 'fully compliant' - Hannon Armstrong "issued the following statement in response to baseless allegations made in a fallacious short attack report by Muddy Waters Capital LLC on July 12, 2022. For more than 40 years, Hannon Armstrong has operated with the highest level of integrity, which includes providing audited, accurate and timely financial statements. Muddy Waters' report questions the integrity of these financial statements by relying on factual errors and inflammatory and misleading statements. Hannon Armstrong believes that its accounting is fully compliant with GAAP and SEC regulations and is an accurate representation of our financial performance. We supplement our GAAP financial statements with certain non-GAAP measures, including a metric we refer to as Distributable Earnings. We believe these non-GAAP measures are a useful supplement to our GAAP earnings for our investors and we fully disclose our Distributable Earnings methodology and adjustments in our SEC filings. In addition to EY serving as our independent auditor, Hannon Armstrong works with another of the "Big Four" accounting firms on risk management and disclosure controls, including on our equity method investments. We believe that this comprehensive approach and commitment to financial integrity is in stark contrast to the false allegations made in the report. The report presents both an array of factual errors and numerous inflammatory and misleading statements demonstrating a fundamental lack of understanding of our financial statements and our business. It insinuates that our non-cash earnings (a) indicate a shortfall in cash available to pay our dividend, (b) result in inflated earnings and (c) reflect distressed borrowers/projects. In fact, our non-cash earnings do not impact our ability to fund our dividend, are intentionally structured at underwriting and are not indicative of distress."

16:46 EDT National Bank of Canada raises Canadian prime rate to 4.7% from 3.7% - National Bank announced an increase in its Canadian prime rate by 100 basis points to 4.70%, effective July 14, 2022.

16:35 EDT Innoviva sells 15% stake in Theravance Respiratory to Royalty Pharma for $282M - Innoviva (INVA) "announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company (TBPH), which receives royalties stemming from sales of TRELEGY ELLIPTA, to Royalty Pharma plc (RPRX) for an upfront cash payment of approximately $282M and a potential $50M contingent sales-based milestone payment. Under the terms of the agreement, TRC also transferred to Innoviva all of TRC's ownership interests and investments in InCarda Therapeutics Inc., ImaginAb, Inc., Gate Neurosciences, Inc. and Nanolive SA. Innoviva retained its royalty rights with respect to ANORO ELLIPTA and RELVAR/BREO ELLIPTA. The sale is expected to close in July 2022. Theravance Biopharma has entered into a concurrent transaction to sell its 85% economic interest in TRC to Royalty Pharma. As a part of the transaction, Innoviva, Theravance Biopharma and GSK signed customary release of claims relating to conduct prior to the closing, including with respect to prior disputes regarding TRC's investment activity."

16:32 EDT Royalty Pharma confirms purchase of royalty interest in Trelegy Ellipta - Royalty Pharma (RPRX) announced that it has agreed to acquire a royalty interest in Trelegy Ellipta from Theravance Biopharma (TBPH) and Innoviva (INVA) for $1.31B in cash up front and up to $300M in additional payments contingent on the achievement of certain sales milestones. The acquisition is expected to close within ten business days. Royalty Pharma is acquiring from Theravance and Innoviva all of the equity interests in Theravance Respiratory Company, LLC, which is entitled to an upward tiering royalty of 6.5% to 10% on annual worldwide Trelegy sales, payable by GSK (GSK). Royalty Pharma will pay to Theravance 85% of the royalties in respect of ex-U.S. net sales after June 30, 2029 and 85% of the royalties in respect of U.S. net sales after December 31, 2030. Royalty Pharma is also providing Theravance $25M in upfront funding and a potential $15 million regulatory milestone to support the clinical development of ampreloxetine, an investigational once-daily norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Neurogenic orthostatic hypotension is a rare disorder in which the autonomic system fails to regulate blood pressure properly, resulting in low blood pressure upon standing. In exchange, Royalty Pharma will receive a low- to mid-single digit royalty on worldwide sales of ampreloxetine. Based on the current analyst consensus estimate, Royalty Pharma expects this transaction to add at least $200M to Adjusted Cash Receipts in 2025, resulting in enhanced long-term growth. Royalty Pharma expects to fund this transaction with existing cash on the balance sheet and to maintain significant financial capacity to deploy capital in additional value-creating opportunities.

16:30 EDT Royalty Pharma confirms purchase of royalty interest in Trelegy Ellipta - Royalty Pharma (RPRX) announced that it has agreed to acquire a royalty interest in Trelegy Ellipta from Theravance Biopharma (TBPH) and Innoviva (INVA) for $1.31B in cash up front and up to $300M in additional payments contingent on the achievement of certain sales milestones. The acquisition is expected to close within ten business days. Royalty Pharma is acquiring from Theravance and Innoviva all of the equity interests in Theravance Respiratory Company, LLC, which is entitled to an upward tiering royalty of 6.5% to 10% on annual worldwide Trelegy sales, payable by GSK (GSK). Royalty Pharma will pay to Theravance 85% of the royalties in respect of ex-U.S. net sales after June 30, 2029 and 85% of the royalties in respect of U.S. net sales after December 31, 2030. Royalty Pharma is also providing Theravance $25M in upfront funding and a potential $15 million regulatory milestone to support the clinical development of ampreloxetine, an investigational once-daily norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Neurogenic orthostatic hypotension is a rare disorder in which the autonomic system fails to regulate blood pressure properly, resulting in low blood pressure upon standing. In exchange, Royalty Pharma will receive a low- to mid-single digit royalty on worldwide sales of ampreloxetine. Based on the current analyst consensus estimate, Royalty Pharma expects this transaction to add at least $200M to Adjusted Cash Receipts in 2025, resulting in enhanced long-term growth. Royalty Pharma expects to fund this transaction with existing cash on the balance sheet and to maintain significant financial capacity to deploy capital in additional value-creating opportunities.

16:21 EDT Tradeweb backs FY22 CapEx view $62M-$68M - Backs FY22 adjusted expenses view $620M-$655M.

16:21 EDT Victory Capital reports AUM of $154.9B as of June 30, 2022 - Victory Capital Holdings reported assets under management of $154.9B as of June 30, 2022, and average assets under management for the second quarter period of $165.7B. The company also reported long-term net flows in the second quarter were -$0.6B, resulting in positive year-to-date long-term net flows of $2.4B.

16:19 EDT United Insurance announces review of strategic and capital raising alternatives - United Insurance "announced that its Board of Directors has initiated a review of its strategic and capital raising alternatives. As part of this process, the Board will consider a wide range of options for the Company including, amongst other things, a potential sale, merger, subsidiary divestiture, formation of a new Florida-domiciled reciprocal exchange, as well as the sale of equity, surplus notes or other financing or strategic transactions."

16:16 EDT Tradeweb Markets names Thomas Pluta president - Tradeweb Markets announced that markets veteran Thomas Pluta has been appointed as its next President. He will join the firm as President-elect in October and become President on January 1, 2023, when current President Billy Hult succeeds Lee Olesky as CEO. As previously announced, Olesky will retire as CEO at the end of 2022 and continue as Chairman through 2023. Lee Olesky, Chairman and CEO of Tradeweb, commented: "Tom Pluta is a superb addition to Tradeweb as the company looks ahead to its next phase of growth. At one point or another, Tom's relationship with Tradeweb has included client, trader, investor and board member, and that broad perspective will be a great asset to Billy Hult's leadership team as well as to the board. We wish Tom all the best in his new role."

16:16 EDT Veracyte says new data published in PLOS ONE show Percepta GSC 'highly accurate' - Veracyte announced that new data published today in PLOS ONE show that the company's Percepta Genomic Sequencing Classifier is highly accurate in re-classifying lung cancer risk among patients with lung nodules whose bronchoscopy results are inconclusive. The authors also conclude that, based on findings from the large, multi-cohort study, use of the genomic test could enable a significant portion of patients to avoid unnecessary and invasive diagnostic procedures and offer the potential for earlier diagnosis. "Quickly and accurately determining whether lung nodules identified through screening or incidentally are benign or malignant is critical to improve patient outcomes, but is often challenging. Physicians frequently use bronchoscopy to evaluate potentially cancerous lung nodules because it is less invasive than surgery, however, many times this procedure produces inconclusive results, leaving physicians and patients without clear guidance about what to do next," said Bill Bulman, M.D., Veracyte's medical director for lung cancer. "The findings from this study suggest that the Percepta GSC provides accurate, objective information that can help resolve this challenge."

16:14 EDT Ensysce Biosciences says 1st patients dosed in PF614 abuse potential study - Ensysce Biosciences, announced the first patients dosed in the PF614-103 study, 'A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users' is being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials. This trial is designed to test and confirm that manipulating and snorting PF614 will not result in subjects liking the product as a recreational drug. Dr. Nily Osman, Chief Medical Officer of Ensysce, commented, "This Human Abuse Potential, HAP, study is a critical step in seeking to establish that, unlike the current opioid analgesics on the market which can be abused through nasal inhalation, PF614 does not carry this risk. Our clinical development of PF614 is rapidly advancing with the initiation of this study. The Trypsin Activated Abuse Protection, TAAP. proprietary drug delivery technology that is used with PF614 requires endogenous human trypsin in the small intestine for its activation, and as such substantially reduces the risk of misuse, abuse, and diversion through inhaled and IV routes by those who use recreational drugs. Our goal is to bring to market a responsible analgesia solution that will alleviate suffering for those who experience severe pain."

16:13 EDT Angi Inc. reports June revenue up 16% - The company said, "Current monthly trends across IAC's businesses reflect the changing macro environment. Dotdash Meredith June Digital revenue was impacted by softening advertiser demand as well as site migrations delays and sales force integration. Conversely, Angi saw accelerating growth in June driven by its Ads and Leads business as the supply/demand dynamic normalizes following the negative impact from the pandemic over the past 2 years as well as continuing to lap the March 2021 rebrand. We will provide further analysis of the results when we report Q2 earnings in August."

16:12 EDT TimkenSteel to purchase $250M group annuity contract from Prudential - TimkenSteel entered into an agreement to purchase a group annuity contract from Prudential (PRU) to settle approximately $250M of the company's approximate $800M in U.S. pension obligations under the TimkenSteel Corporation Bargaining Unit Pension Plan. In connection with the agreement, Prudential will pay future benefits under the group annuity contract starting October 1, 2022, for a specified group of approximately 1,900 retirees and beneficiaries who are currently receiving payments from the Pension Plan. Benefits payable to the retirees and beneficiaries and to other Pension Plan participants will not be reduced as a result of this transaction. The group annuity contract will be purchased using existing assets of the Pension Plan and requires no cash contribution from the company. Once finalized, this annuity purchase is expected to reduce TimkenSteel's U.S. pension obligation by approximately $250M, or 25%. The company expects to realize a non-cash pension settlement gain of approximately $2M in Q3.

16:10 EDT ContraFect announces DSMB recommendation to stop DISRUPT study - ContraFect announced that the Data Safety Monitoring Board, or DSMB, of the DISRUPT study has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because the conditional power of the study was below the pre-specified threshold for futility. The recommendation was based on an analysis of the clinical response rate at day 14 in 84 patients, or approximately 60% of the total planned methicillin-resistant Staphylococcus aureus, or MRSA, population with bacteremia, including right-sided endocarditis. While further review of the data is ongoing, the company is initiating steps to notify investigators that patient enrollment in the trial is being stopped based on the DSMB recommendation. "This disappointing news reflects the long history of difficulties in treating life-threatening infections like MRSA bacteremia in patients with heterogeneous co-morbidities, and who are in need of immediate life-saving treatments. We are sincerely grateful to all the patients, their families and the investigators who participated in the trial," stated Roger Pomerantz, ContraFect's president, CEO, and chairman.

16:08 EDT CytomX Therapeutics to restructure business, reduce workforce by 40% - CytomX Therapeutics announced plans to focus on its emerging pre-clinical and early clinical pipeline and to realign its capital resources to drive these efforts. The company is restructuring its business to prioritize internal investments in its emerging pre-clinical and early clinical pipeline, resulting in a reduction to its workforce, primarily development and general and administrative staff, by approximately 40%. These changes are expected to extend the company's cash runway into 2025. CytomX is maintaining its research, translational and early development organizations to support ongoing internal pipeline efforts with two Investigational New Drug Applications planned for 2023. CytomX remains committed to its current alliances with AbbVie, Amgen, Astellas, and Bristol Myers Squibb, which include the clinical-stage programs CX-2029, CX-904, and BMS-986249. CEO Sean McCarthy commented, "This difficult decision to restructure CytomX regrettably leads to the departure of many valued team members who have been dedicated to our vision and mission and whose contributions have been critical to the Company's success to date. On behalf of myself and the Board of Directors, we thank them for their efforts and wish everyone the very best in their future endeavors."

16:06 EDT NerdWallet Chief Marketing Officer Kelly Gillease to step down - NerdWallet "announced that Chief Marketing Officer Kelly Gillease will be stepping down from her role effective October 1, 2022. Following Gillease's departure, Brand Marketing, Communications, and Organic Marketing will report directly to Chief Executive Officer, Tim Chen, while Customer Relationship Marketing and Performance Marketing will be split between Chief Product Officer, John Caine, and Chief Business Officer, Kevin Yuann. This structure is intended to enable NerdWallet to continue building consumer awareness and trust in its brand while tightening alignment between marketing activities and key products and initiatives. Chen will continue to focus on setting the vision for NerdWallet and ensuring all teams are set up to execute on the company's strategic priorities. Gillease will serve as a consultant to NerdWallet to assist in the transition following her departure."

16:04 EDT Workday granted FedRAMP Authorized status - Workday has achieved FedRAMP Authorized status at the Moderate security impact level from the Federal Risk and Authorization Management Program - FedRAMP - for Workday Government Cloud, marking the company's official entry into the U.S. federal government market. With FedRAMP authorization status, which is required of cloud technology vendors in the federal sector, Workday is now certified by the federal government in meeting the cloud security requirements and work with help federal agencies.

15:53 EDT Bank of Nova Scotia raises Canadian prime lending rate to 4.7% from 3.7% - Scotiabank announced that it is increasing its Canadian dollar prime lending rate to 4.7% from 3.7%, effective July 14.

15:48 EDT TD Canada Trust raises prime rate to 4.7% from 3.7% - TD Canada Trust announced that it has increased its TD Prime Rate by 100 basis points to 4.7%, effective July 14, 2022.

15:47 EDT Scotiabank raises prime lending rate to 4.7% from 3.7% - Scotiabank announced that it is increasing its Canadian dollar prime lending rate to 4.7%from 3.7%, effective July 14, 2022.

15:25 EDT Uber faces lawsuit from women passengers over sexual misconduct claims - Uber Technologies has been named in a civil action alleging that women passengers in multiple states were k"idnapped, sexually assaulted, sexually battered, raped, falsely imprisoned, stalked, harassed, or otherwise attacked by Uber drivers with whom they had been paired through the Uber application." The complaint was filed Wednesday in San Francisco County Superior Court by attorneys at Slater Slater Schulman LLP, a full-service law firm focused on representing survivors of catastrophic and traumatic events. Slater Slater Schulman LLP has approximately 550 clients with claims against Uber, with at least 150 more being actively investigated. "Uber's whole business model is predicated on giving people a safe ride home, but rider safety was never their concern - growth was, at the expense of their passengers' safety," said Adam Slater, Founding Partner of Slater Slater Schulman LLP. "While the company has acknowledged this crisis of sexual assault in recent years, its actual response has been slow and inadequate, with horrific consequences." Reference Link

15:17 EDT Dave & Buster's CEO buys 33,400 shares of common stock at $30.54 - In a regulatory filing, Dave & Buster's disclosed that CEO Christopher Morris acquired 33,400 shares of Dave & Buster's stock on July 13 at an aggregate price of $30.54 per share.

14:55 EDT General Dynamics awarded up to $280M for Active Protection System kits for tanks - General Dynamics Land Systems, a business unit of General Dynamics, announced that it has been awarded a competitive award worth up to $280,112,700 to procure Trophy Ready Kits as an Active Protection System for Abrams main battle tanks. Work on the indefinite delivery, indefinite quantity contract is expected to extend into mid-2027. "We are honored to have been chosen by the Army to continue to provide this important capability to keep tank crew members and their vehicles safe on the battlefield," said Gordon Stein, vice president of U.S. operations at General Dynamics Land Systems.

14:33 EDT Netflix to partner with Microsoft on new ad supported subscription plan - Greg Peters, Netflix (NFLX) Chief Operating Officer and Chief Product Officer, stated in a post to the company's site: "In April we announced that we will introduce a new lower priced ad-supported subscription plan for consumers, in addition to our existing ads-free basic, standard and premium plans. Today we are pleased to announce that we have selected Microsoft as our global advertising technology and sales partner. Microsoft has the proven ability to support all our advertising needs as we work together to build a new ad-supported offering. More importantly, Microsoft offered the flexibility to innovate over time on both the technology and sales side, as well as strong privacy protections for our members. It's very early days and we have much to work through. But our long term goal is clear. More choice for consumers and a premium, better-than-linear TV brand experience for advertisers. We're excited to work with Microsoft as we bring this new service to life." Reference Link

14:05 EDT Accenture to acquire commerce agency The Stable, terms not disclosed - Accenture announced it has agreed to acquire The Stable - a commerce agency focused on helping consumer brands build and operate their own digital commerce channels as well as manage their brand and sales performance across key North American retailers. "The agreement reinforces Accenture's continued investments in commerce to help clients accelerate growth and sustain relevance," the company stated. Completion of the acquisition is subject to customary closing conditions. Terms of the transaction were not disclosed.

13:32 EDT North American rail traffic rose 1.1% for the week ending July 9 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending July 9. For this week, total U.S. weekly rail traffic was 437,600 carloads and intermodal units, down 3.1% compared with the same week last year. Total carloads for the week ending July 9 were 207,450 carloads, down 1.3% compared with the same week in 2021, while U.S. weekly intermodal volume was 230,150 containers and trailers, down 4.7% compared to 2021. North American rail volume for the week ending July 9, on 12 reporting U.S., Canadian and Mexican railroads totaled 302,763 carloads, up 1.9% compared with the same week last year, and 311,439 intermodal units, up 0.3% compared with last year. Total combined weekly rail traffic in North America was 614,202 carloads and intermodal units, up 1.1%. North American rail volume for the first 27 weeks of 2022 was 18,170,988 carloads and intermodal units, down 3.4% compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) ,Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:11 EDT Gold Resource reports Q2 preliminary production of 11,475 gold equivalent ounces - Gold Resource Corporation sold a total of 8,746 ounces of gold and 231,622 ounces of silver in Q2 2022 for a gold equivalent total of 11,475 ounces. Additionally, the Company sold 3,590 tonnes of zinc, 286 tonnes of copper, and 1,755 tonnes of lead contributing to a strong cash balance of over $33M. Allen Palmiere, President and CEO said "Production remains solid at the Don David Gold Mine in Mexico and the feasibility study continues to advance at the Back Forty Project in Michigan. While the volume of tonnes processed during the quarter dipped at DDGM, grades and recoveries helped ensure we delivered another quarter of over 10 thousand gold equivalent ounces."

12:04 EDT CAE unveils new brand identity, logo - CAE unveiled its new visual brand identity and logo to reflect its bold vision for the future, and further support its high-tech culture and mission. The company said, "This evolution reinforces CAE's mission to prepare people in critical roles for the moments that matter, equipping them with the expertise and solutions to create a safer world using advanced technologies that elevate safety standards, human performance, and outcomes. CAE marks these changes as it celebrates 75 years of industry-firsts, a remarkable journey distinguished by the organization's noble purpose to make the world a safer place." CAE's new visual brand identity and logo will be progressively deployed across its global network of 200 sites in over 35 countries.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -15.3% - ProShares UltraShort Bloomberg Natural Gas is down -15.3%, or -$4.59 to $25.35.

12:00 EDT SilverBow Resources rises 9.4% - SilverBow Resources is up 9.4%, or $2.45 to $28.68.

12:00 EDT ironSource rises 42.8% - ironSource is up 42.8%, or 95c to $3.19.

11:47 EDT Sony says more 'Assassin's Creed' titles coming to PlayStation Plus service - Sony's (SONY) PlayStation said in a blog post that Ubisoft+ Classics, a curated selection of Ubisoft (UBSFY) games included with PlayStation Plus Extra and PlayStation Plus Premium plans, is adding multiple "Assassin's Creed" titles to its growing library on July 19. On July 19, the following games become available on PlayStation Plus with Ubisoft+ Classics: The Ezio Collection, including Assassin's Creed II, Assassin's Creed Brotherhood, and Assassin's Creed Revelations; Assassin's Creed IV: Black Flag and its Freedom Cry expansion; Assassin's Creed Unity, and; Assassin's Creed Rogue Remastered. Reference Link

11:41 EDT Novan announces publication of 'positive' Phase 3 results in JAMA Dermatology - Novan announced the publication of "positive" efficacy and safety data from its completed B-SIMPLE 4 pivotal Phase 3 clinical study evaluating berdazimer gel, 10.3% for the treatment of molluscum in the peer-reviewed journal, JAMA Dermatology. Berdazimer Sodium in Molluscum Patients with Lesions 4 was a multicenter, vehicle-controlled, double-blind study, which enrolled 891 patients across 55 clinics in the United States that were 6 months or older with 3 to 70 raised molluscum lesions. Enrolled patients were randomized to treatment with berdazimer gel, 10.3%, or vehicle gel, applying a thin layer to lesions once daily for 12 weeks. At the end of 12 weeks, 32.4% of patients in the berdazimer group achieved complete clearance of lesions as compared to 19.7% in the vehicle group. Adverse event rates were low, the most common were mostly mild application-site pain and erythema. In June 2021, Novan reported a statistically significant greater treatment effect as compared to vehicle for the primary efficacy endpoint of complete clearance of all treatable lesions at Week 12. "Novan is proud to have conducted the largest molluscum interventional trial and to have achieved the results we did. If approved, berdazimer gel, 10.3% could be the first FDA-approved prescription product for the treatment of this highly contagious viral skin infection that mostly affects children. We are continuing our preparations to submit a New Drug Application for berdazimer gel, 10.3% and remain on target to do so before the end of 2022," commented Paula Brown Stafford, President and CEO of Novan.

11:36 EDT Kontrol announces funding to accelerate Kontrol BioWater development - Kontrol Technologies announces that its operating subsidiary CEM Specialties is receiving advisory services and funding of up to $300,000 from the National Research Council of Canada Industrial Research Assistance Program supporting a research and development project to accelerate its new wastewater testing technology, the Kontrol BioWater analyzer for the detection of viruses including COVID-19.

11:33 EDT Duke Energy raises quarterly dividend to $1.005 per share - Duke Energy declared a quarterly cash dividend on its common stock of $1.005 per share, an increase of 2c. This dividend is payable on Sept.16, 2022, to shareholders of record at the close of business on Aug.12, 2022.

11:05 EDT Masimo termintes consumer division president Kevin Duffy - On April 11, 2022, Masimo appointed Kevin Duffy as its President, Consumer Division in connection with the company's acquisition of Viper Holdings. On July 11, the company sent Duffy a notice of termination without cause of his employment with the company, effective as of August 5. Duffy has agreed to remain with Masimo until August 5, and to assist the company with transition and other matters on an as-needed basis following the termination of his employment, Masimo disclosed in a regulatory filing.

11:02 EDT AI-LINK selects Keysight's 5G test tools for performance validation - Keysight Technologies announced that AI-LINK has selected Keysight's 5G test tools for end-to-end performance validation of cloud-native 5G radio access network equipment in a digital twin laboratory environment, which accelerates 5G private network deployments for large-scale smart warehouse applications.

10:41 EDT Infosys to acquire BASE life science for up to EUR 110M - Infosys announced a definitive agreement to acquire BASE life science, which it calls "a leading technology and consulting firm in the life sciences industry in Europe." Infosys said: "The acquisition reaffirms our commitment to help global life sciences companies realize business value from cloud-first digital platforms and data, to speed-up clinical trials and scale drug development, positively impacting lives and achieving better health outcomes. BASE brings to Infosys, domain experts with commercial, medical, digital marketing, clinical, regulatory, and quality knowhow. Backed by a team of data science specialists, BASE is at the frontier of the latest technological developments and trends. It has a strong focus on Data & AI, and the ability to bridge and integrate business logic and technology, driving insights for better health outcomes." The acquisition is expected to close during the second quarter of fiscal 2023, subject to customary closing conditions. The cost of the acquisition is up to EUR 110M, including management incentives, bonuses and retention, according to a notice to stock exchanges shared by the company. Reference Link

10:36 EDT T-Mobile, Deutsche Telekom announces Spoke to use T IoT for safer cycling - T-Mobile (TMUS) and Deutsche Telekom (DTEGY) announced that Spoke, a mobility platform for safety, connectivity and rich rider experiences, will use T IoT to help bicyclists and motorists share the road more safely. T IoT, a comprehensive solution for global IoT connectivity, platform management and support, will power Spoke's new hardware and software system that delivers near real-time information to bicyclists and motorists on the road, to help them reach their destination safely.

10:33 EDT Rio Tinto invests $188M to increase low-carbon billet production in Canada - Rio Tinto is investing $188M to increase the production capacity for low-carbon, high value aluminium billets at its Alma smelter in Lac-Saint-Jean, Quebec by 202,000 metric tonnes. The existing casting center at Rio Tinto's Alma plant will be expanded to accommodate newequipment, including a casting pit and furnaces, allowing a larger portion of the aluminium produced to be converted to higher value billets. Construction will begin in May 2023, after completing detailed engineering and preliminary work, and commissioning is expected in the first quarter of 2025. The investment will strengthen the supply chain in North America and allow Rio Tinto to be more agile and flexible to support the critical growth of North American manufacturers for a variety of high value-added products, primarily in the automotive and construction industries. Aluminium billets are extruded through a die and the resulting profiles are used to make various products like bumpers and roof rails for cars as well as doors and window frames. The investment is expected to generate nearly $160M in economic benefits for Quebec. The project will create around 40 new permanent jobs and help to support the 770 existing jobs at the Alma plant.

10:23 EDT Global SPAC Partners Company (Units) trading resumes

10:21 EDT Delta Air Lines sees CASM ex-fuel 22% in Q3

10:14 EDT Delta Air Lines sees 2022 capacity 15% lower than 2019

10:11 EDT PMN Stock trading resumes

10:07 EDT Delta sees capacity at June levels, or 80% of 2019, through end of year

10:05 EDT Delta Air Lines reports 99.2% completion factor through first 11 days in July - Over last 7 days, Delta has had only 25 cancellations worldwide, says CEO Ed Bastian.

10:04 EDT Canoo drops 5% after disclosing Walmart pact prevents sales to Amazon - Canoo shares are down 5% to $3.46 in morning trading.

10:03 EDT Delta's June revenue was 4% ahead of 2019, June operating margin 16.5%

10:02 EDT Delta CEO notes 'challenging' operating environment for the entire industry - Comments taken from Q2 earnings conference call.

10:02 EDT PepsiCo Beverages North America acquires 152 acres of land in Denver - PepsiCo Beverages North America announced that it acquired nearly 152 acres of land at the Denver High Point development area where it will build a 1.2 million square foot manufacturing facility. Set to open in 2023, the new facility is PBNA's latest project as part of its near 75-year investment in the Denver community, including the company's River North Art District location that has been in operation since the 1950s, the company said in a statement, adding that this new development, located near the intersection of 72nd Avenue and Argonne Street, holds three times the capacity of the current facility and will be PBNA's largest U.S. plant location.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -7.5% - ProShares UltraShort Bloomberg Natural Gas is down -7.5%, or -$2.23 to $27.71.

10:00 EDT Unity Software falls -14.0% - Unity Software is down -14.0%, or -$5.56 to $34.20.

10:00 EDT Seabridge Gold rises 6.6% - Seabridge Gold is up 6.6%, or 74c to $11.89.

09:55 EDT Canoo says Walmart agreement prevents sales to Amazon - Canoo (GEOV) yesterday morning announced that entered into an electric vehicle fleet purchase agreement with Walmart (WMT), pursuant to which Walmart agreed to purchase at least 4,500 electric vehicles manufactured by Canoo, with an option to purchase up to an additional 5,500 EVs, for an agreed price per unit to be determined based on the model but capped at an agreed upon amount. Canoo disclosed this morning that under the agreement, it has agreed that, for the duration of the agreement, it will not enter into any agreement for any services involving the design, manufacture, consult, advice, lease, or sale of EVs to, or issue any equity, equity-linked or debt securities of any type, or enter into any agreement for the purpose of transferring control of the company to Amazon.com (AMZN), its subsidiaries, or affiliates. Shares of Canoo are little changed at $3.61 in early trading.

09:54 EDT SodexoMagic awarded agreement for on-site management services with Premier - SodexoMagic, the joint venture between Magic Johnson Enterprises and Sodexo (SDXAY), was awarded a national GPO agreement for on-site management services of Environmental Services, Facilities Management, and Patient Transportation with Premier (PINC). The new agreement allows Premier members, at their discretion, to utilize their Tier 1 and Tier 2 supplier diversity spends for the goods, services, and labor contracted directly through SodexoMagic in environmental services, facilities management, and patient transportation departments.

09:50 EDT Global SPAC Partners Company trading halted, volatility trading pause

09:47 EDT Ads-Tec Energy apppoints Wolfgang Breme as CFO - ADS-TEC Energy (ADSE) announces the expansion of its management team: Wolfgang Breme has been appointed CFO of the ADS-TEC Energy Group effective as of July 1, 2022. As a member of the Executive Board, he was responsible for Finance and Administration at AIXTRON SE (AIXXF) for almost a decade. The CFO of ads-tec Energy GmbH, Mr. Robert Vogt, remains the Chief Accounting Officer of the ADS-TEC Energy Group.

09:47 EDT GrafTech falls -9.0% - GrafTech is down -9.0%, or -61c to $6.18.

09:47 EDT Web Street, Inc. rises 6.4% - Web Street, Inc. is up 6.4%, or $2.96 to $48.97.

09:47 EDT ironSource rises 50.2% - ironSource is up 50.2%, or $1.12 to $3.35.

09:40 EDT Hindenburg announces 'significant long position' in Twitter - Hindenburg Research said via Twitter, "We have accumulated a significant long position in shares of Twitter. Twitter's complaint poses a credible threat to Musk's empire."

09:37 EDT Archer Exploration to acquire Grasset nickel deposit from Wallbridge Mining - Archer Exploration is pleased to announce that it has entered into a definitive asset purchase agreement dated July 12, 2022 with Wallbridge Mining Company. Pursuant to the Asset Purchase Agreement, Archer will acquire all of Wallbridge's nickel assets, rights and obligations located in Quebec and Ontario. Archer is backed by Inventa Capital Corp., a Vancouver-based merchant bank founded in 2017 with the goal of discovering and funding opportunities in the resource sector. The Nickel Assets consist of 2,046 mining titles covering approximately 67,000 hectares and include a 100% interest in the Grasset nickel sulphide project located in Quebec Pursuant to the Asset Purchase Agreement, Archer will acquire the Nickel Assets from Wallbridge in exchange for 198,635,786 Archer Shares at a deemed value of C$0.27 per Consideration Share for a purchase price of approximately C$53.6M. In addition to issuing the Consideration Shares, Archer will also grant Wallbridge a net smelter return royalty on production from the Grasset Project. Wallbridge has agreed to complete a partial distribution of Consideration Shares by way of a reduction of stated capital to its shareholders on a pro rata basis within 60 days of closing of the Transaction. Following the Share Distribution, Wallbridge will own 19.9% of the Archer Shares following closing of the Transaction and related matters. The Transaction will constitute a "Fundamental Change" of Archer within the meaning of the policies of the Canadian Securities Exchange. Completion of the Transaction is subject to a number of conditions precedent, including, but not limited to: acceptance by the CSE and receipt of other applicable regulatory approvals; receipt of approval of the shareholders of Archer; completion by Archer of a private placement for gross proceeds of at least C$10,000,000; and certain other closing conditions customary for a transaction of this nature. Upon completion of the Transaction and the Share Distribution: current shareholders of Archer will hold approximately 15% of the Archer Shares on a fully-diluted in the money basis, and Wallbridge and shareholders of Wallbridge will hold approximately 85% of the outstanding Archer Shares on a fully-diluted in the money basis. In connection with the Transaction, Archer entered into a finder's fee agreement dated as of June 10, 2022 with two arm's length parties. As compensation for the Finders' introduction of Archer and Wallbridge, should the Transaction be completed, Archer will pay to the Finders collectively a number of Archer Shares equal to 2.5% of the number of Consideration Shares. The finder's fee is subject to approval of the CSE. Any Archer Shares issued to the Finders will be subject to escrow and released over a period of two years after closing of the Transaction. The Finders have agreed to notify Archer of any potential disposition of Archer Shares and allow Archer the opportunity to designate the purchase of all or any portion of such shares. In connection with closing of the Transaction, Archer and Wallbridge will enter into a royalty agreement, an investor rights agreement, and an exploration cooperation agreement.

09:32 EDT Afterpay, Sephora partner for installment payments - Afterpay announced a partnership with Sephora to offer customers the flexibility to pay in four installments when shopping for their favorite beauty brands and products in the U.S. The companies said, "The partnership underscores both brands' commitment to address their customers' needs and will deliver an omnichannel experience that makes purchasing everyday beauty essentials easy, convenient and accessible to more shoppers." The BNPL payment service is anticipated to expand to Sephora Canada later this year.

09:23 EDT Lexaria Bioscience's human nicotine study nearing start date - Lexaria Bioscience announces the pending start of its upcoming human nicotine study NIC-H22-1. Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH, leads to enhanced oral-tissue absorption and reduced negative experiences. Study NIC-H22-1 is a minimum 36-person human pharmacokinetic randomized, double blinded, cross-over study to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn. Objective data collection from blood samples that will evidence Tmax, Cmax, and AUC is the primary objective of the study. Secondary objectives include extensive subjective evaluations related to throat burn, user experience, and more. The nicotine test article ingredient manufacturing and DehydraTECH processing have been completed and those processed materials have been received by the third-party pouch manufacturing company for filling and packaging. Independent Review Board approval and subsequent human dosing will be the next two major steps in this study.

09:20 EDT Nokia reports change in shares - A total of 175 261 Nokia shares held by the company were transferred without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 72 784 100.

09:18 EDT Stagwell acquires PEP Group, terms not disclosed - Stagwell announced the acquisition of PEP Group, an omnichannel content creation and adaptation production company. In response to the explosion in new media channels that require a streamlined and scalable approach to producing multi-market assets, PEP Group will join Locaria, Stagwell's multilingual content agency, to bolster its media and content production capabilities across its global network. Terms were not disclosed.

09:16 EDT Cue Health appoints Allison Blackwell as Chief Human Resources Officer - Cue Health has appointed Allison Blackwell as Chief Human Resources Officer, effective immediately. Blackwell most recently served as Vice President, Global Diversity + Inclusion for Danaher. Prior to that, Blackwell served as VP, Human Resources for Danaher's Diagnostics and Life Sciences platform, including through a number of milestones and acquisitions. Prior to her tenure at Danaher, Blackwell served as Senior VP, Human Resources & Communications, at Beckman Coulter.

09:12 EDT Fujifilm announces $350M investment in U.S. Electronic Materials business - FUJIFILM Electronic Materials, U.S.A. announced the strategic investment of $350M in its U.S. business during its fiscal year period FY21 - FY23. This $350M represents approximately 35% of Fujifilm's planned global investment of nearly $1B into its electronic materials business, including capital investment and R&D enhancements to meet expanding demand. This demand is based on expected long-term semiconductor market growth and the critical role that Fujifilm's specialized chemicals and materials play in the semiconductor supply chain. The planned U.S. investment will support the development and manufacture of Fujifilm's broad range of semiconductor materials and chemicals, particularly Chemical Mechanical Polishing slurry and Photolithography-related high purity materials. The investment will enable the continued expansion of manufacturing, quality, and R&D equipment at the company's existing sites in Arizona, Rhode Island, Texas, and California. In addition to the capital investment, the company plans to add at least 120 new positions in chemistry, engineering, manufacturing, warehousing, and maintenance, by the end of 2024.

09:07 EDT GBS announces key milestone in prospective study comparing glucose samples - GBS announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health's Mills-Peninsula Medical Center, MPMC, in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types. Daniel Brown, PhD, CCRC and Head of Clinical Affairs for GBS stated, "While a systematic literature review reveals numerous clinical investigations of salivary glucose levels, we at GBS believe that this is the first clinical study to utilize an independent, validated, traceable reference measurement to characterize glucose in oral fluids. We are privileged to collaborate with the Diabetes Research Institute and Johns Hopkins University to complete this important research and thank them in their support in this study. We look forward to continued statistical analysis of the data generated during this study." Key Points to Highlight: The clinical study followed an IRB-approved protocol; 40 adult subjects with type 2 diabetes were recruited for the study; Nearly 1400 samples of blood and oral fluids were collected and analyzed; GBS used independent glucose measurement procedures to quantitate glucose in oral fluids and blood; GBS engaged with Johns Hopkins University; Analysis of the resulting data will explore the degree of agreement among glucose levels in oral fluid and blood samples by subject and across the entire cohort.

09:06 EDT EnWave obtains SQF certification for REVworx - EnWave announced that its vacuum-microwave toll drying facility, REVworx, has completed the Safe Quality Food certification process, marking the Company's ability to offer toll drying services to food producing partners around the globe. Following a thorough SQF certification process incorporating training, line trial production, testing, inspection, and process development, REVworx is now officially open for business, offering on-demand contract manufacturing services for the production of high-quality, vacuum-microwave dried snack and ingredient applications for food companies of all sizes. EnWave's pursuit and achievement of SQF certification solidifies their commitment to continual and ongoing food safety processing in the REVworx facility going forward. REVworx, as an SQF Certified facility for Fruits & Vegetables Processing, Bakery and Snack Processing, and Food Ingredient Manufacturing, can now offer contract REV drying services to a broader market. REVworx clients are assured that their products are adding the value of REV technology to their product offering, as well as meeting the highest levels of food safety standards.

09:06 EDT Flex commits to net zero greenhouse gas emissions by 2040 - Flex released its 2022 sustainability report, which summarizes the company's global sustainability activities, performance and results from calendar year 2021. In tandem with the report's release, the company announced a commitment to reach net zero greenhouse gas emissions by 2040, doubling down on climate action efforts.

09:05 EDT Kodak announces investment in company developing EV 'Super Cell' battery - Eastman Kodak announced it has taken a minority stake in Wildcat Discovery Technologies, a technology company that uses proprietary high-throughput methods to rapidly develop new battery materials. Wildcat is developing a breakthrough EV "super cell" designed to provide a greater than 90 percent improvement in energy density over today's best batteries, which could further accelerate the widespread adoption of EVs. Kodak's investment will be used to support rapid development of the new technology, with the goal of having the "super cell" ready for commercialization in two years. Kodak has also entered into an agreement to provide coating and engineering services in collaboration with Wildcat to develop and scale film coating technologies which are critical for the safety and reliability of the next generation of EV battery technology. Wildcat has granted Kodak certain rights to negotiate a production or licensing arrangement with Wildcat when and if Wildcat's technology reaches commercial readiness. "This investment in Wildcat reflects Kodak's commitment to building new businesses by leveraging our existing skills and infrastructure. Coating substrates is a critical aspect of manufacturing batteries and no one is better at coating than Kodak," said Jim Continenza, Kodak's Executive Chairman and CEO. "We are excited about the opportunity to collaborate with an innovator like Wildcat to provide more powerful, safer solutions for applications such as energy storage and EV batteries and participate in this rapidly growing market."

09:03 EDT AvidXchange announces purchase-to-pay integration for Sage 100 - AvidXchange announced an end-to-end, purchase-to-pay, P2P, integration available for Sage 100 customers in AvidStrongroom. This new offering builds on the company's suite of solutions integrated with Sage technology including, Sage Intacct, Sage 100 Contractor and Sage 300 CRE. With this launch, AP professionals and business leaders can reduce time spent manually matching purchase orders, invoices and receipts by automating those tasks in AvidStrongroom. Furthermore, the platform recognizes different approval workflows based on the results of the PO matching process creating opportunity for a more efficient process and less risk of error in the future. "This new integration is a testament of AvidXchange's commitment to improving our solutions to meet the unique needs of our customers," said Dan Drees, Chief Growth Officer of AvidXchange. "With this integration, our customers will have a more streamlined AP process that allows them to save time and resources so that they can focus on driving their businesses and not manual processes."

09:03 EDT AvePoint hires Murray as Chief Channel Officer - AvePoint (AVPT) announced the appointment of Heather Murray as Chief Channel Officer, CCO. In this role, Murray will lead the company's efforts to expand relationships with managed service providers, solution providers, and systems integrators, grow the Global Partner Program, and accelerate global distribution networks and cloud marketplace presence. Murray is a channel veteran who joins AvePoint from TD SYNNEX (SNX). The company also appointed Angela Choo as VP of Channel, Asia. Choo previously led the APAC business and managed strategic partnerships at BitTitan.

08:43 EDT Gladstone Commercial appoints EJ Wislar as CIO - Gladstone Commercial Corporation announced that its board of directors appointed EJ Wislar as its Chief Investment Officer, effective July 12, 2022. Mr. Wislar joined the Company in 2018 and will continue to serve as Head of the Southeast and Northeast Regions, where he is responsible for acquisitions, asset management and the Profit & Loss of the regions. In addition, on July 1, 2022, Buzz Cooper became the sole President of the Company, following the previously announced retirement of Bob Cutlip. Prior to Mr. Cutlip's retirement, he and Mr. Cooper served as Co-Presidents since January of this year.

08:41 EDT CytoDyn appoints Arman as President - CytoDyn announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022. Dr. Arman will be responsible for determining and leading the Company's operating strategy for the future. It is anticipated that he will advance to Chief Executive Officer and be appointed to the Board of Directors within six months. Antonio Migliarese, who had been serving as interim President since late January, in addition to CFO, will resume his previous role as CFO. Dr. Arman brings over 15 years of industry experience. Most recently, Dr. Arman served as Chief Business Officer for Nimble Therapeutics.

08:40 EDT Fast Radius partners with Simbe Robotics for component manufacturing - Fast Radius has partnered with Simbe Robotics to manufacture components critical to the function and aesthetics of their advanced inventory robot, Tally 3. Simbe has reimagined the possibilities of automation to create new efficiencies in retail stores and selected Fast Radius' Cloud Manufacturing Platform because of its ability to bypass current supply chain disruptions through flexible production. This results in faster time to market versus traditional manufacturing processes and helps the business scale. Tally 3, Simbe's flagship robot, is an autonomous retail intelligence robot that drives productivity and customer satisfaction by collecting and analyzing inventory data in retail environments, such as the shelf-stocking needs of grocery stores. Deterred by the heavy startup costs of injection molding parts, Simbe needed to achieve precise results from less expensive manufacturing methods - namely urethane casting - in order to quickly expand their fleet of robots and meet growing demand from retailers.

08:38 EDT Grove releases letter to shareholders from CEO Marshall - Grove released a letter to shareholders from Chief Executive Officer, Allan Marshall. "In our first year of operation as a public company we navigated the challenges of Covid-19, extreme inflationary pressure, employee shortages, along with transportation and logistics delays affecting all aspects of our business. Despite these significant headwinds, we managed to complete our IPO, consolidate multiple acquisitions, and hit both our projected growth and profitability targets while remaining cash flow positive... As we review our successes, it is incumbent upon us to identify areas in need of improvement. It has come to my attention that our communication with investors could be better. In addition, our customer service has not always lived up to our high standards. In response, we are implementing many quality control procedures in an effort to improve all aspects of service to our customers now and going forward... What started as a CBD company has grown into a multifaceted operation of profitable related businesses, with multiple Direct to Consumer Brands, an SAAS Technology advertising business focused on programmatic email advertising and ad services and our newest addition of an Amazon based liquidation company. The future growth will come from our Upexi Brand aggregation business, and acquisitions that expand our technology and liquidation business segments... Our cash flow from operations increased over fiscal year 2022 and we remain committed to that trend continuing as our revenue grows. We have a solid balance sheet for future growth with the use of debt and equity to maximize shareholder value... We look to strengthen our vendor relationships for long-term, lasting partnerships in each industry we touch. Increasing our focus and communication with the investment community and building relationships with investors is a top priority for fiscal year 2023."

08:37 EDT CACI gets IAC MAC $557.8M order for US Navy digital engineering, transformation - CACI International announced that it was awarded a $557.8M single-award task order under the Department of Defense Information Analysis Center Multiple Award Contract, IAC MAC,vehicle to provide mission expertise for the transition of modern digital tools into the U.S. Navy acquisition enterprise for the Navy's Digital Integration Support Cell and Naval Surface Warfare Center Crane. CACI's support includes analysis, development, and planning for the transition of programs of record into newly developed or updated technology systems. The team will leverage standards and practices necessary to integrate advanced capability into distributed maritime operations, supporting advanced mission kill chains in an integrated, interoperable environment.

08:36 EDT Compass Diversified completes acquisition of PrimaLoft - Compass Diversified announced the completion of the Company's previously announced acquisition of PrimaLoft Technologies Holdings, the parent company of PrimaLoft, from Victor Capital Partners and minority owners, pursuant to an agreement entered into on June 4, 2022. The acquisition was completed for a purchase price of $530M. The Company funded the acquisition via a new $400M five-year Term Loan A loan and amended its existing credit agreement to extend its $600M Revolver through July 2027. CODI's initial equity ownership in PrimaLoft is approximately 91%. PrimaLoft's management team and existing shareholders invested alongside CODI and own the remaining 9%. "We are excited to have completed our acquisition of PrimaLoft and look forward to partnering with their experienced leadership team to capitalize on the significant market opportunities ahead," said Elias Sabo, CEO of Compass Diversified. "PrimaLoft has earned the trust of over 950 leading brands and we're pleased to support its next phase of growth."

08:36 EDT Sabre's SynXis tourism distribution platform selected by Hotel M's in Japan - Sabre announced a new agreement with Hotel M's in Kyoto, Japan, to help the chain to grow geographic reach and attract international travelers as Japan eases border restrictions. To prepare for, and capture, the expected influx of tourism, Hotel M's Co. Ltd has inked a new technology agreement with Sabre. The deal will enable the chain to put its inventory in front of travel agents globally across all major Global Distribution Systems through Sabre Hospitality's SynXis platform. Established in 2014, the chain has 16 hotels across Kyoto city, opening one close to Kyoto Station during the pandemic in anticipation of future inbound tourists.

08:34 EDT Marsh McLennan increases quarterly dividend 10.3% to 59c per share - The board of directors of Marsh McLennan declared a 10.3% increase in the quarterly dividend from 53.5c to 59c per share on outstanding common stock, payable on August 15 to stockholders of record on July 28.

08:33 EDT Bristow Group pre-orders 100 hybrid-electric cargo VTOL aircraft from Elroy Air - Bristow Group has signed a Letter of Intent with Elroy Air to pre-order 100 Chaparral hybrid-electric cargo VTOL aircraft. The Chaparral will be the first of its kind vertical take-off and landing - VTOL - aircraft dedicated to cargo movement to be introduced into Bristow's aircraft fleet. Bristow plans to use the Chaparral to serve logistics, healthcare, and energy applications. The LOI is expected to be replaced with a separate purchase agreement.

08:32 EDT ABVC BioPharma provides ADHD Phase II Part 2 clinical update - ABVC Biopharma announced the enrollment progress in the Phase II Part II clinical study of the Company's ADHD medicine, ABV-1505. Since results on the first subject treated were reported on May 10, 2022, a total of 22 subjects have been enrolled in the study from a total of 32 subjects screened. One of the enrolled participants from the three arms completed the 8-week treatment per the study design. The study, a randomized, double-blind, placebo-controlled study, titled "A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder, Part II," is expected to eventually enroll approximately 100 patients. "We are pleased to see 22 subjects have been enrolled in the Phase II Part II ADHD clinical trial, and one participant has completed the 8-week treatment," said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma. "We expect to maintain the strong recruiting rates and look forward to announcing more study progress."

08:28 EDT Auto services provider chooses Bridgeline Digital's TruPresence - TruPresence announced it was chosen by a global auto services provider to help power their franchise digital marketing for their US-based locations. The auto services provider, with over 1,000 locations globally, has selected TruPresence to implement its SEO auditing and analysis suite to increase the local digital footprint of every location as well as brand awareness and search engine rankings at the national level.

08:26 EDT Siyata Mobile, Logic Wireless launch SD7 rugged PoC device - Siyata Mobile announces Logic Wireless Europe will introduce the Siyata SD7 rugged PoC device integrated with ChatterPTT. ChatterPTT is Logic Wireless's mobile application and gateway solution that intelligently enables different types of communication devices to communicate directly with each other.

08:19 EDT CanadaHelps launches Charity Growth Academy initiative - CanadaHelps announced the launch of the CanadaHelps Charity Growth Academy, an initiative made possible by Mastercard and its new Mastercard Changeworks program. Charity Growth Academy is a free digital transformation program to help Canadian charities become more digitally enabled. Through the program, charities will build technical skills, improve their operational processes, and develop digital mindsets by leveraging the training, expert support, grants, and tools of the program. The national initiative is now underway with a pilot program of 11 organizations from across Canada. The pilot program will run through April 2023.

08:17 EDT Lincoln Educational to open new campus in Atlanta - Lincoln Educational Services announced plans to open the Company's second campus in the metropolitan Atlanta area. The new 55,000 square foot campus, with capacity for approximately 700 students, will be located near Interstate 85 to conveniently offer training programs in Auto Technology, Electrical & Electronic Systems Technology, Welding, and Heating, Ventilation & Air Conditioning to students from Atlanta as well as south of the city. It will complement Lincoln's existing Marietta, GA campus to the north which provides career training in healthcare support fields along with skilled trades programs. The new campus is projected to open in the third quarter of 2023, subject to obtaining necessary regulatory approvals and timely build-out. Lincoln will deploy its new hybrid education delivery model providing greater flexibility for students and faculty. The planned curricula at the new campus are in industries that are anticipated to add a combined 84,000 jobs across Georgia by 2028. The Company believes the new campus will play a major role in expanding career opportunities for graduates as well as building the state's workforce for these vital, growing fields. This new campus is the first of five new campuses the Company plans to open nationwide within the next five years. The Company projects the new campus will generate approximately $20M in revenue and $5M in earnings before interest, taxes, depreciation and amortization within four years of opening. The Company also believes, based on employer demand for skilled employees and job growth projections, that it may be able to open as many as 20 new campuses as part of its long-term strategic plan.

08:13 EDT OncoCyte announces market entry, early adopter program with VitaGraft - Oncocyte Corporation announced that it has completed development and clinical validation of the Laboratory Test for its newly-branded VitaGraft Transplant Monitoring tests for Liver and Kidney, entering a $2B US market. The company also opened an Early Adopter Program, EAP, giving access to leading transplant centers prior to a potential CMS coverage decision and full commercial launch. VitaGraft, formerly branded as Therasure, is a patented, proprietary test built upon the IP acquired in the Chronix Biomedical acquisition last year. "In less than nine months, we have completed tech transfer, developed and completed clinical validation of the VitaGraft program in both Liver and Kidney, and submitted for Medicare reimbursement," said Ron Andrews, CEO of Oncocyte. "I'm also pleased to announce that, on a parallel path, we have initiated development of the VitaGraft IVD assay. Our goal is to utilize our patented technology to support better care and faster access to results for patients and physicians in the transplant community. We look forward to giving regular updates on our progress as we anticipate achieving reimbursement and launching our FDA study over the next several quarters."

08:11 EDT Twist Bioscience, DNAnexus team on data analysis software for NGS workflow - DNAnexus and Twist Bioscience announced a collaboration aimed at accelerating research and reducing the time to design, validate, and commercialize new, high-quality, next-generation sequencing, NGS, based diagnostic tests. As part of the collaboration, Twist customers are able to use the integrated DNAnexus platform with Twist's NGS Methylation Detection System and Unique Molecular Identifier, UMI. Adapter System to simplify data analysis after sequencing. The Twist NGS Methylation Detection System provides robust sample preparation and target enrichment solutions for identifying methylated regions in the human genome. Rare diseases, cancer, and other disorders can be identified by unique methylation patterns within samples. The NGS Methylation Detection System uses highly sensitive hybridization capture-based technology that can be integrated into diagnostic tests. This workflow can also be used to better characterize and understand the genetic mechanisms linked to specific conditions including cancer, neurodegeneration, and rare diseases. The Twist UMI Adapter System detects low-frequency variants in low-input sample sources such as cell-free DNA and can be used to enable cancer research. The DNAnexus platform allows users to easily explore and analyze complex datasets in a single, scalable, cloud-based environment.

08:09 EDT Cerence, CerebrumX collaborate to build AI-powered platform built on AWS - CerebrumX and Cerence announced a strategic collaboration to offer an AI-powered platform built on Amazon Web Services, AWS, that drives effective data and actionable insights from millions of connected vehicles in real-time. Combining the power of the Cerence Connected Vehicle Digital Twin, CVDT, platform, CerebrumX Augmented Deep Learning Platform, ADLP, and AWS, the companies developed an intelligent AI-powered connected vehicle data platform that is scalable, easy-to-use, and intuitive within a proven, reliable cloud infrastructure. Automakers can use this platform to create responsive in-vehicle services. The solution also provides valuable product insights back to the OEM to improve services and empower future offerings. This connected vehicle AI solution, built on AWS, enables the entire automotive ecosystem to scale its operations while creating new revenue streams for OEMs. "We are excited to expand our work with CerebrumX and together with AWS invest in powering enhanced in-car user experiences," said Prateek Kathpal, Executive Vice President and Chief Technology Officer, Cerence. "Cerence CVDT is gaining traction among OEMs and quickly becoming the center point of real-time connected car view. Together, we are creating new applications, services, and opportunities along with data monetization, benefiting both drivers and automakers."

08:08 EDT VERB announces American Ninja Warrior apparel joining Shopfest - Verb Technology announced that NBC sports entertainment reality show American Ninja Warrior apparel is joining Shopfest. Shopfest marks the official launch of Verb's MARKET platform, a social shopping and livestream ecommerce platform that represents the convergence of live entertainment and shopping.

08:07 EDT Booz Allen forms $100M corporate venture capital arm - Booz Allen announced the formation of Booz Allen Ventures, a $100M corporate venture capital arm that furthers the firm's commitment to invest in strategic dual-use, commercial technologies that will provide federal clients disruptive technology for critical missions. Booz Allen Ventures will invest in early-stage companies and technologies within four core areas of demand: defense, artificial intelligence/machine learning, cybersecurity, and deep technology.

08:05 EDT OrthoPediatrics announces distribution agreement with 3D-Side - OrthoPediatrics announced an exclusive distribution agreement with 3D-Side S.A., a Belgium based software developer and manufacturer of patient specific 3D printed cutting guides. This commercial agreement grants OrthoPediatrics exclusive distribution rights of the 3D-CUT-OSTEO osteotomy guide in the United States' leading pediatric hospitals in addition to certain international markets in the future. OrthoPediatrics' President and CEO David Bailey commented, "the 3D-Side technology complements the OrthoPediatrics' pediatric limb deformity implant and biologic offering, and increases exposure in the pediatric oncology market, where many of the most challenging orthopedic cases involving tumor resection require a full complement of solutions including implants, biologics, and patient specific devices. We are excited to enter this relationship with 3D-Side to provide our pediatric orthopedic customers access to the 3D-CUT products."

08:05 EDT Lightning eMotors partners with Amply to enable integration of OMEGA software - AMPLY Power announced the first deployment of its "Powered by AMPLY" offering, enabling OEMs to integrate AMPLY's charge management software with their electric vehicles-making the electrification process for fleets easier than ever. AMPLY partnered with Lightning eMotors, a leader in zero emission vehicles, to launch the new offering. With Powered by AMPLY, Lightning will combine the strength of its own vehicle telematics with AMPLY's OMEGA charge management software for new EV purchases. "We are thrilled to be integrating our class-leading vehicle telematics solution, Lightning Insights, with AMPLY Power, one of the leaders in the fleet charging management space," said Tim Reeser, Chief Executive Officer of Lightning eMotors. "Tight integration between vehicles and chargers is a critical component of successful fleet electrification, electric load management, and operating cost control. This joint integration between OMEGA and Insights will enable fleets to deploy Lightning EVs with confidence that they can leverage AMPLY's software to optimize the fleet operation and charging strategy 'out of the box'."out AMPLY Power

08:03 EDT Crocs granted favorable infringement verdict against USA Dawgs, Double Diamond - Crocs announced a judgment of infringement against USA Dawgs and Double Diamond Distribution as a result of both companies' sales of imitation Crocs shoes. In conjunction therewith, Crocs also obtained $6M and $55K in damages, respectively, against the companies. This case is the culmination of years long battles between the parties after USA Dawgs and Double Diamond Distribution began selling shoes that infringed Crocs' patents in 2006. Both USA Dawgs and Double Diamond Distribution have since conceded the validity of Crocs' patent rights.

08:03 EDT ViaSat delivers second ViaSat-3 payload module to Boeing's El Segundo facility - Viasat (VSAT) announced delivery of the second ViaSat-3 payload module to Boeing's (BA) El Segundo, CA facility where it will be integrated with Boeing's 702 spacecraft bus platform and undergo rigorous spacecraft environmental testing in preparation for launch. The second ViaSat-3 class satellite is expected to provide broadband service over Europe, the Middle East and Africa in 2023.

08:01 EDT WillScot Mobile Mini acquires Modulease Corporation - WillScot Mobile Mini announced it has acquired the rental fleet and related assets of Modulease Corporation. The transaction was funded with cash on hand and borrowings under the Company's revolving credit agreement. This acquisition adds more than 400 mobile offices and approximately 100 portable storage containers to the Company's existing operations in New England.

07:45 EDT Theratechnologies announces binding commitment for term loan up to $100M - Theratechnologies announced that it has received a binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management for up to $100M. The facility is subject to the terms and conditions of a credit agreement. Highlights of the agreement are as follows: Senior secured term loan of up to $100M available across multiple tranches; $40M is expected to be funded on or before July 29, 2022; $20M to be made available through June 2023, subject to the satisfaction of defined milestones; $15M to be made available through March 2024 subject to the satisfaction of defined milestones; An additional $25M will be available to Theratechnologies until December 2024 upon meeting certain defined milestones; The facility will have an initial term of five years provide for an interest-only period of 24 months, and bear interest at the Secured Overnight Financing Rateplus 9.50%, subject to a SOFR floor of 1.00%; and, The Company has agreed to purchase $30M of the principal amount of the Convertible Notes due June 2023, at a discount to par, in privately negotiated agreements with United States based noteholders, which are expected to close on or before July 29, 2022.

07:36 EDT FDA grants De Novo marketing authorization to Apollo ESG, Apollo REVISE systems - Apollo Endosurgery announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE and Apollo REVISE Sx Systems through the U.S. Food and Drug Administration's De Novo Classification process. These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision.

07:32 EDT CloudMD launches telemedicine, physical health coaching service for Kii - CloudMD Software & Services announced that it has launched a national telemedicine and physical health coaching service as part of its Kii Personalized & Connected Care offering. Kii, the Company's flagship employer health and wellness solution, integrates several of its technologies and services into one exceptional, connected, and personalized experience. The new telemedicine medical care program provides a personalized treatment plan led by nurses and nurse practitioners and supported by primary care doctors and specialists. The nurses and nurse practitioners are trained to deliver comprehensive initial medical assessments, psychosocial healthcare support and treatment for most primary and mental healthcare issues. They act as the first point of contact for referrals to specialists and other important services offered within Kii, to help guide individuals through their personalized healthcare journey.

07:32 EDT OLB Group announces 1M share repurchase program - OLB Group announced that its board of directors has authorized a share repurchase program of up to 1M shares of its outstanding shares of common stock.

07:17 EDT Kaleyra rejects unsolicited proposal to acquire the Campaign Registry subsidiary - Kaleyra has rejected an unsolicited offer from TCR Acquisition to acquire 100% of the Campaign Registry, a wholly owned subsidiary of Kaleyra. The Board of Directors of the company unanimously concluded that the unsolicited, non-binding proposal from TCR Acquisition significantly undervalues The Campaign Registry and its prospects for continued growth, and is not in the best interests of the company and its shareholders. The Campaign Registry, a reputation authority for the 10-digit long code business messaging campaign ecosystem, works with North American mobile operators and companies in the messaging business to provide visibility into campaign messaging source and content, allowing mobile carriers to provide a more reliable and simple messaging service for Campaign Service Providers and Brands.

07:16 EDT NRx Pharmaceuticals names Stephen Willard as CEO - NRx Pharmaceuticals announced the appointment of Stephen Willard, as its CEO and a member of the company's Board of Directors. The company's interim CEO, Robert Besthof, will continue to support the company and return to his roles as Head of Operations and Chief Commercial Officer. Most recently, Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price.

07:11 EDT Dundee provides update on Constitutional Protective Action in Ecuador - Dundee Precious Metals announced that an oral decision on the Constitutional Protective Action filed against the Ministry of Environment, Water and Ecological Transition was delivered by the Judicial Labour Unit of Cuenca. The decision upheld the validity of the Company's environmental permits for exploration at Loma Larga, confirmed that the MAATE did not violate certain rights relating to the protection of water and nature in granting the permits, and reaffirmed DPM's mining concessions for Loma Larga. The court also found that the Company will be required to include the local indigenous populations in its consultation process prior to proceeding to the exploitation phase, which DPM had already planned as part of its development of the project, reflecting Company's commitment to the highest standards of stakeholder engagement and in-line with International Finance Corporation practices. The written decision is expected to be delivered within a week's time, following which the claimants have three days to file an appeal of the decision. During this time, DPM's drilling activities will remain paused, pending the Company's assessment of the written decision and the impact of any appeals that are filed. The Company continues to work closely with the MAATE as well other local stakeholders to advance permitting for the project, which recently included the receipt of the technical viability certificate for the filtered tailings storage facility at the end of June.

07:09 EDT Manitou Gold identifies nickel-iron alloy in drill core - Manitou Gold announced the identification of a naturally occurring nickel alloy mineral in discovery hole MTU-22-14, which returned 0.25% Ni over 48 metres. Geophysical interpretation has outlined 60 kilometres of structures hosting interpreted ultramafic intrusions with large tonnage nickel potential within the orogenic gold target area on 100% owned Manitou lands comprising the Goudreau project. Highlights: Goudreau area confirmed as emerging 'Juggernaut' for gold production with nearly 10 Moz of gold resources and reserves being developed and mined on Manitou's western flank. Identification of awaruite, a naturally occurring nickel alloy with high nickel content in previously released discovery hole MTU-22-14, which returned 0.25% Nickel and 100 ppm Cobalt over 48 m. Identification of three structural trends with over 60 km cumulative strike length of ultramafic intrusions with nickel potential; total surface area of prospective nickel targets is at least 2.8 km. Acquisition of contiguous mining claims covering newly identified ultramafic intrusions in the prolific Michipicoten greenstone belt bringing the Company's combined land holdings to 366 km2 in the region. Manitou Gold's Goudreau project is comprised of largely contiguous mineral claims and patents in the eastern Michipicoten gold belt in northern Ontario. The Goudreau project is situated between Argonaut Gold's Magino mine and Alamos Gold's Island Gold mine to the west and, to the east, the past-producing Renabie mine owned by Barrick Gold. Major geological structures in the gold camp provide the main controls on gold mineralization and include the Goudreau-Lochalsh deformation zone , which hosts both the Island Gold and Magino deposits, and the Baltimore deformation zone, which represents the eastern fault offset extension of the GLDZ on Manitou ground. As the largest land holder in the belt, controlling 366 square kilometers of prospective mining lands surrounded by major gold deposits, Manitou is uniquely positioned for discovery of additional gold deposits in one of the fasted growing gold districts in North America. In addition, recent exploration has highlighted the potential for large tonnage ultramafic hosted nickel deposits analogous to Dumont and Crawford.

07:04 EDT Orthofix, LimaCorporate announce licensing partnership in U.S. - Orthofix and LimaCorporate announced a licensing partnership for the U.S. market to provide a novel solution for patients with the challenging condition of chronic high dislocation of the hip.

07:04 EDT Optinose announces results from ReOpen trial evaluating XHANCE - Optinose announced results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for treatment of patients with chronic sinusitis. XHANCE nasal spray is a drug-device combination product combining its proprietary Exhalation Delivery System, EDS, designed to uniquely deliver drug high and deep in nasal passages with an anti-inflammatory drug. These analyses of pooled data from the ReOpen1 and ReOpen2 trials found that over 24 weeks of follow-up, patients using XHANCE two sprays per nostril twice daily had 66% reduction in the number of disease exacerbations compared to patients receiving a placebo comparator. Acute exacerbations, or "flares", are a major source of disability for the roughly 30 million patients in the United States who suffer from chronic sinusitis. ReOpen1 and ReOpen2 are controlled clinical trials in patients with CT-scan proven chronic sinusitis. Both trials were previously reported to have shown that XHANCE treatment resulted in reduction of inflammation inside the sinus cavities and reduction in a combined symptom score. Analysis of pooled data from the 2 trials found a statistically significant reduction of 66% in the incidence of exacerbations for patients receiving 2 sprays twice daily of XHANCE compared to placebo comparator. In additional exploratory pre-planned analyses, similar reductions in the number of exacerbations were also found for patients taking XHANCE one spray per nostril twice daily, and in subgroups either with or without nasal polyps."This is the first Phase 3 program we are aware of showing that a nasal medication can significantly reduce the number of acute exacerbations of chronic sinusitis," said Ramy Mahmoud, MD, MPH, President of Optinose. He went on to say, "This is important because these episodes not only lead to poor quality of life but also often push people to frequent use of antibiotics, oral steroids, or even surgery.2 If a new treatment can prevent these events from occurring and reduce use of antibiotics, oral steroids, or even sinus surgery, it could be very meaningful for a large population of sufferers and for society."

07:03 EDT XORTX reports topline results from Pharmacokinetics Bridging Study - XORTX Therapeutics announced topline results from Part 1 of the three part Pharmacokinetics Bridging Study - XRX-OXY-101 - showing a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation compared to a control formulation. In addition, accompanying the improved bioavailability findings in Part 1 of the PK Clinical Trial was a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol. Successful recruitment, administration of a single oral dose of drug formulation, blood sampling and bioanalytical evaluation were conducted in Part 1 of the PK Clinical Trial to characterize the pharmacokinetics and bioavailability of the unique proprietary formulations in advance of the Company's planned late-stage phase 3 registration trial in autosomal dominant polycystic kidney disease. The PK Clinical Trial is undertaken in three parts and designed with four important objectives: to determine which of XORTX's novel formulations results in the greatest circulating oxypurinol concentrations and oxypurinol exposure; to determine the effect of food on the bioavailability of the selected formulation; to determine the effect of dose on the bioavailability of the selected formulation; and to determine the safety and pharmacokinetics of multiple doses of the selected formulation. Knowledge gained during the conduct of this PK Clinical Trial will provide guidance regarding the formulation selected and the oral dosing regimen necessary to reach and maintain the target circulating concentration of oxypurinol. Part 1 of the PK Clinical Trial involved dosing under fasted conditions. Part 2 will measure the effect of food on pharmacokinetics and Part 3 is a multiple dose pharmacokinetics evaluation. The PK Clinicial Trial is designed to permit XORTX to characterize the safety and relative bioavailability of the XRx-008 program formulations. Knowledge gained during the conduct of this PK Clinical Trial is now providing critical guidance regarding the oral dosing for our planned phase 3 registration trial in ADPKD. Part 1 of the XRX-OXY-101 achieved the following purposes: Confirmed improved human bioavailability of XORTX formulations of oxypurinol for future development; Established a pharmacokinetics data set characterizing oral bioavailability of XORTX formulations for future population based pharmacokinetic modeling; Confirmed the unique proprietary formulation innovations from recently granted US and EU patents that provide for increased circulating concentrations of oxypurinol; and Built upon the pharmacokinetic and safety database of safety and efficacy for oxypurinol.

06:57 EDT Spirit Airlines announces intention to adjourn Special Meeting of Stockholders - Spirit Airlines (SAVE) announced that, in response to the request set forth in the letter to the company from Frontier Group Holdings (ULCC) dated July 10, Spirit intends to reopen and immediately adjourn its Special Meeting of Stockholders relating to the proposed merger agreement with Frontier until July 27 at 11:00am ET, at which time the Special Meeting will reconvene. Spirit will continue to solicit proxies from its stockholders with respect to the proposed merger with Frontier, and will continue discussions with Frontier and JetBlue Airways (JBLU). The Spirit Board of Directors reiterates its commitment to the Frontier transaction and strongly recommends stockholders vote FOR the merger on the WHITE proxy card today. All stockholders of record as of the close of business on May 6 are entitled to vote at the Special Meeting. Spirit stockholders who have not already voted, or wish to change their vote, are strongly encouraged to submit their proxies as soon as possible. Valid proxies submitted by stockholders prior to the adjourned Special Meeting will continue to be valid for purposes of the reconvened Special Meeting.

06:47 EDT Lazard reports June 2022 AUM of $216.6B - Lazard reported preliminary assets under management - AUM - as of June 30, 2022 totaled approximately $216.6B from $235.95B as of May 31. The month's AUM included market depreciation of $13.1B, foreign exchange depreciation of $3.7B, and net outflows of $2.5B. Preliminary average assets under management for the quarter ended June 30, 2022 were $225.7B.

06:38 EDT Biolase announces pilot program with Einstein Healthcare Network's residency - Biolase announced a pilot program with Einstein Healthcare Network's residency in General Dentistry to train General Dentist residents in the use of Waterlase dental laser technology. The goal of the program is to offer residents hands-on experience with dental lasers that are becoming the gold standard of care in dentistry, allowing residents to immediately implement this technology when they enter their future practice.

06:09 EDT Gevo signs five year supply agreement to provide aviation fuel to Aer Lingus - Gevo announced a new fuel sales agreement with Aer Lingus, owned by International Airlines Group, or IAG. The Agreement provides for Aer Lingus to purchase 6.3 million gallons per year of sustainable aviation fuel - SAF - for five years from Gevo's future commercial operations. Aer Lingus expects to commence fuelling its aircraft with SAF from Gevo in 2026. The expected value for the Agreement is deemed to be $173M, inclusive of the value from environmental benefits for Gevo. As part of International Airlines Group, Aer Lingus has pledged to achieve net-zero carbon emissions by 2050 and has committed to powering 10% of its flights using sustainable aviation fuel by 2030. Gevo expects to continue to pursue its stated goal of producing and commercializing one billion gallons of SAF by 2030. The Agreement with Aer Lingus is subject to certain conditions precedent, including Gevo developing, financing, and constructing one or more production facilities to produce the SAF contemplated by the Agreement.

06:06 EDT Deep Medicine Acquisition enters combination agreement with Chijet Motor - Deep Medicine Acquisition Corp. announced the signing of a definitive business combination agreement, dated July 12, with Chijet Motor Company, a Chinese automaker, which is developing next-generation electric vehicles and expanding its manufacturing capabilities. Chijet expects to use the transaction proceeds to fund the development and production of its planned next-generation electric vehicle, with sales expected to increase as new models are launched and two production facilities, occupying a total area of 8.47M square feet with annual production capacity of 200,000 vehicles currently under construction in Xiangyang and Yantai, China, are completed. The business combination attributes an implied enterprise value to Chijet's operating companies of $2.55B in the aggregate, including Chijet's 85.17% ownership interest in Shandong Baoya New Energy Vehicle Co., Ltd., the Chinese company that is developing new EV models, and 64.82% interest in FAW Jilin, the Chinese company producing and selling traditional fuel vehicles. Upon completion of the transaction, Chijet is expected to have approximately $127.8M in cash, assuming no redemptions by DMAQ public shareholders. The cash proceeds raised in the transaction are currently anticipated to be used for the construction of Chijet's Yantai electric vehicle manufacturing base and to fund company operations, support its growth and for general company operating purposes. Following completion of the proposed transaction, Chijet plans to raise additional capital to further its planned expansion of production capacity and product offering to include new models of electric vehicles. In the proposed transaction, both Chijet and DMAQ will be acquired by a newly-formed holding company named Chijet Motor Company, which is expected to be listed on the Nasdaq Stock Market. The boards of directors of DMAQ and Chijet have unanimously approved the proposed transaction. Its closing is subject to approval by DMAQ stockholders, completion of DMAQ's satisfactory due diligence review of Chijet within 60 days of entering into the business combination agreement and is subject to other customary closing conditions, including the U.S. SEC declaring Pubco's registration statement effective and the expiration of the applicable HSR Act waiting period. It is currently expected that the transaction will close by the end of the fourth quarter of 2022, assuming such closing conditions are met.

06:04 EDT Pluristem's PLX-PAD shows muscle regeneration efficacy in Phase 3 study - Pluristem announced topline results from its multinational Phase III study designed to determine efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture. PLX-PAD was demonstrated to be an effective accelerator of muscle strength and regeneration. A significant increase in Hip Abduction Strength was observed at week 26 and week 52 for patients treated with PLX-PAD in the injured leg and uninjured leg vs. placebo. This new data confirms the results demonstrated in Pluristem's phase I/II study. The study did not meet the primary endpoint, which was the Short Physical Performance Battery test at week 26, a series of physical performance tests used in older persons to assess lower extremity function and mobility. PLX-PAD was well tolerated and demonstrated a significant increase in HAS. When comparing the absolute HAS between study groups, treated vs. placebo, at week 52, patients treated with PLX-PAD showed a 2.6kg higher score than placebo treated patients in the injured leg. A similar benefit was seen in the uninjured leg, with a 2.2kg difference. The increase in HAS was further supported by a positive trend in a 6-minute walk test at week 52, showing an increase in walking distance, which is an acceptable functional endpoint. Pluristem will seek further regulatory advice to find a way to bridge the gap between the clear impact on muscle strength and the functionality score.

05:12 EDT InMed Pharmaceuticals receives noncompliance notification from Nasdaq - InMed Pharmaceuticals announced that the company received written notice from the listing qualifications department staff of Nasdaq notifying it that the closing bid price of the company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550.

05:08 EDT Planet Labs Germany expands collaboration with BKG - Planet Labs announced that its wholly owned subsidiary, Planet Labs Germany, has signed a new contract with the German Federal Agency for Cartography and Geodesy, or BKG, to provide the agency with daily, high-resolution satellite data for crisis response, environmental and nature conservation, as well as forest and agricultural monitoring. Access to Planet's satellite data will help the BKG promote public and civil safety throughout the Federal Republic of Germany. The collaboration was launched in November 2021 and is now being expanded following a successful trial period.

05:04 EDT Rocket Lab announces successful launch of first NRO responsive space mission - Rocket Lab has successfully launched the first of two responsive space missions for the National Reconnaissance Office, or NRO. Following lift-off of NROL-162 from Pad A at Rocket Lab Launch Complex 1 at 06:30 UTC, July 13, Electron successfully delivered the NRO's national security payload to space. In partnership with the Australian Department of Defence, NROL-162 will provide information to the United States Government's agencies and allies and national security decision makers monitoring and responding to world events and humanitarian issues.